[
  {
    "ts": null,
    "headline": "Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off",
    "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]",
    "url": "https://finnhub.io/api/news?id=d1b87fd9d1607fcb0d7ebfd9c5dfb7bc04f5bd29a4bcf64b01c0fd8aeab54363",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743018011,
      "headline": "Jim Cramer Highlights Johnson & Johnson (JNJ) as a Rare Winner Amid Market Sell-Off",
      "id": 133462056,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]",
      "url": "https://finnhub.io/api/news?id=d1b87fd9d1607fcb0d7ebfd9c5dfb7bc04f5bd29a4bcf64b01c0fd8aeab54363"
    }
  },
  {
    "ts": null,
    "headline": "Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",
    "summary": "The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.",
    "url": "https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743012000,
      "headline": "Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted Returns",
      "id": 133460063,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072585234/image_1072585234.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Dividend Income Accelerator Portfolio focuses on financially healthy companies with strong balance sheets. Check out the recent additions to the portfolio.",
      "url": "https://finnhub.io/api/news?id=ce462cc0e5b7f820a511093e525334e1bca7d2a89963f65cc3b58e557cad4636"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate",
    "summary": "Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a",
    "url": "https://finnhub.io/api/news?id=fff9a4556ed0e684ae8bf06d03fb9d9a07dd44160c30f0e8c2c26f5686009485",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743007049,
      "headline": "Johnson & Johnson Reports Positive Data from Phase 3 Study of Lung Cancer Drug Candidate",
      "id": 133462057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Wednesday that results from a phase 3 trial showed that Rybrevant as a",
      "url": "https://finnhub.io/api/news?id=fff9a4556ed0e684ae8bf06d03fb9d9a07dd44160c30f0e8c2c26f5686009485"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer",
    "summary": "Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substi",
    "url": "https://finnhub.io/api/news?id=8338901da52e0f7881b5626f4504fc996e9cdf897d58f656d8d9eb808ae5dfb8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743003900,
      "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer",
      "id": 133458289,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substi",
      "url": "https://finnhub.io/api/news?id=8338901da52e0f7881b5626f4504fc996e9cdf897d58f656d8d9eb808ae5dfb8"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=044da3b2d7cf3fd7d2abd605ab510c43cc86e0f5c03ee0dac248804e732ca3d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742996410,
      "headline": "Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock",
      "id": 133457199,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=044da3b2d7cf3fd7d2abd605ab510c43cc86e0f5c03ee0dac248804e732ca3d4"
    }
  },
  {
    "ts": null,
    "headline": "J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib",
    "summary": "Johnson & Johnson: * RYBREVANT® PLUS LAZCLUZE™ OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTEDOVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALLCELL...",
    "url": "https://finnhub.io/api/news?id=81a15a55e99dc1f9d1449fd8c8d363db69200415d668a689e6163daa5fb696bc",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742996222,
      "headline": "J&J Says Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib",
      "id": 133458727,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * RYBREVANT® PLUS LAZCLUZE™ OUTPERFORMS OSIMERTINIB WITH A SIGNIFICANT AND UNPRECEDENTEDOVERALL SURVIVAL BENEFIT IN PATIENTS WITH EGFR-MUTATED NON-SMALLCELL...",
      "url": "https://finnhub.io/api/news?id=81a15a55e99dc1f9d1449fd8c8d363db69200415d668a689e6163daa5fb696bc"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=d9865ff417cd6034cf187b07246b2a5bfe33f68604f89ab29403651a4116fcfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742994005,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 133457200,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=d9865ff417cd6034cf187b07246b2a5bfe33f68604f89ab29403651a4116fcfd"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson MedTech introduces electrosurgical generator",
    "summary": "The solution is designed for future compatibility with the company's Ottava Robotic Surgical System.",
    "url": "https://finnhub.io/api/news?id=61740b54647ac30793741d17d1c7ae5a6e4c332a4892573b49159f33e7354618",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742991529,
      "headline": "Johnson & Johnson MedTech introduces electrosurgical generator",
      "id": 133448334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The solution is designed for future compatibility with the company's Ottava Robotic Surgical System.",
      "url": "https://finnhub.io/api/news?id=61740b54647ac30793741d17d1c7ae5a6e4c332a4892573b49159f33e7354618"
    }
  },
  {
    "ts": null,
    "headline": "New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.",
    "url": "https://finnhub.io/api/news?id=166d60ffe3b17a87acfe3371104d36a6f20eececace0cf78ede1695812f52854",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742990580,
      "headline": "New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)",
      "id": 133448336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.",
      "url": "https://finnhub.io/api/news?id=166d60ffe3b17a87acfe3371104d36a6f20eececace0cf78ede1695812f52854"
    }
  }
]